SCHEMBL3300192

SCHEMBL3300192

CCCc1cc(CNC(=O)CN2CCN(c3ccccc3C#N)CC2)nn1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 8/20 0.49
GFER P55789 3/20 0.47
DRD2 P14416 5/20 0.46
DRD3 P35462 4/20 0.45
ALDH1A1 P00352 4/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 2/20 0.43
GAA P10253 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
HTR2A P28223 1/20 0.43
THPO P40225 1/20 0.43
HIF1A Q16665 1/20 0.43
GMNN O75496 1/20 0.42
LMNA P02545 1/20 0.42
THRB P10828 1/20 0.42
PMP22 Q01453 1/20 0.42
MTOR P42345 1/20 0.41
RPTOR Q8N122 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3298239 0.90 KCNH2 (0.53) DRD4GFERDRD2DRD3ALDH1A1
SCHEMBL3296701 0.88 DRD4 (0.54) DRD4GFERDRD2DRD3ALDH1A1
SCHEMBL3306587 0.88 GFER (0.51) GFERALDH1A1MAPTKDM4ECACNA1G
SCHEMBL3300670 0.87 KMT2A (0.52) GFERDRD2ALDH1A1MAPTKDM4E
SCHEMBL3295771 0.84 HTR7 (0.48) GFERALDH1A1MAPTKDM4EHTR2A
SCHEMBL3307008 0.80 MEN1 (0.58) ALDH1A1MAPTKDM4EGAALMNA
SCHEMBL3298259 0.77 CA1 (0.54) ALDH1A1MAPTKDM4EGAALMNA
SCHEMBL3300454 0.77 CACNA1G (0.60) GFERALDH1A1MAPTCACNA1GCACNA1H
SCHEMBL3299904 0.77 ALOX5 (0.51) HIF1ACACNA1GCACNA1HKCNH2
SCHEMBL3299917 0.77 CACNA1G (0.53) DRD2HTR2ALMNACACNA1GCACNA1H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299072-B2 Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-10-30 US claimed
US-20100094006-A1 NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-04-15 US claimed
US-8299072-B2 Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-10-30 US disclosed
US-20100094006-A1 NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100094006-A1 NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF CACNA1I, CACNA1C, ORAI1 DRD4 1788/4885GFER 3476/4885DRD2 1548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.